Equibles does not estimate personal net worth.
Get an email with a short summary when Vir Biotechnology, Inc. publishes a filing, an earnings call transcript or a press release.
Get VIR alertsMarianne De Backer is recorded as CEO at Vir Biotechnology, Inc. (VIR). The proxy statement of Vir Biotechnology, Inc. reports total compensation of $7,834,045 for Marianne De Backer in fiscal 2025, including a base salary of $950,000. Disclosed compensation is on record for 3 fiscal years. Marianne De Backer has spoken on 12 earnings calls across 1 company, most recently for Vir Biotechnology, Inc. on August 5, 2026. Vir Biotechnology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Vir Biotechnology, Inc. includes Marianne De Backer, MSc, Ph.D., MBA (CEO and Board Member), Aziz Sawaf (CFO), Brent Sabatini (CFO) and 7 others.
“And thank you for joining us for VeerBuy Technologies' second quarter 2026 earnings call. During the quarter, we continue to execute cross-hour portfolio, demonstrating meaningful progress in both hepatitis delta and oncology, while further strengthening our regulatory and commercial readiness.”
“Good afternoon, everyone, and thank you for joining us for VirBi Technologies' first quarter 2026 earnings call. Since our last earnings call in February, we have remained highly focused on execution as we advance both our oncology and hepatitis delta programs with speed and focus.”
“Today marks a pivotal moment for VIR biotechnology as we announce a landmark strategic collaboration with Astellas to advance the global development and commercialization of VIR 5500, our Pro-X10 dual-masked PSMA-targeting T-cell engager for prostate cancer.”
“Good afternoon, everyone, and thank you for joining us for Veer Biotechnology's third quarter 2025 earnings call. Today's call will highlight the significant progress we've made and our clear path forward as an organization.”
“Good afternoon, everyone, and thank you for joining us for VirBiTechnology's second quarter 2025 earnings call. I'm excited to share our progress with you today as we've achieved several important milestones across our pipeline this quarter.”
2023-01-01–2024-04-19
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO
2023-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Vir Biotechnology, Inc. (VIR) | M.Sc., Ph.D., MBA President, Chief Executive Officer and Director | $950,000 | $7,834,045 |
| 2024 | Vir Biotechnology, Inc. (VIR) | M.Sc., Ph.D., MBA Chief Executive Officer and Director | $920,833 | $9,255,903 |
| 2023 | Vir Biotechnology, Inc. (VIR) | M.Sc., Ph.D., MBA Chief Executive Officer and Director | $675,000 | $39,491,495 |
